The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation.

@article{Mnch1994TheCD,
  title={The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation.},
  author={Gerald M{\"u}nch and Yavuz Taneli and E Schraven and Ulrike Schindler and Reinhard Schinzel and Dieter Palm and Peter Franz Riederer},
  journal={Journal of neural transmission. Parkinson's disease and dementia section},
  year={1994},
  volume={8 3},
  pages={193-208}
}
Non-enzymatic glycosylation of proteins, also called Maillard reaction, which occurs at an accelerated rate in diabetes, can lead to the formation of advanced glycosylation endproducts (AGEs). Tenilsetam (CAS 997: (+/-)-3-(2-thienyl)-2-piperazinone), a cognition-enhancing drug successfully used for treatment of patients suffering from Alzheimer's disease, when included in the Maillard reaction apparently inhibits protein crosslinking by AGEs in vitro. According to the mechanism proposed… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…